Neurological Surgery 脳神経外科42巻12号

2014年12月発行

連載 脳卒中専門医に必要な基本的知識

（5）脳梗塞慢性期内科治療

著者： 田口芳治¹

所属機関： ¹富山大学附属病院神経内科

ページ範囲：P.1159 - P.1171

Ⅰ．はじめに
　脳梗塞慢性期の内科的治療は，脳梗塞再発予防と後遺症対策，うつ症状や誤嚥性肺炎などの合併症治療が中心となる．脳梗塞再発予防としては，抗血栓療法と危険因子の管理が重要であるが，best medical treatmentを行うためには，正しい脳梗塞の病型と病態の診断のもとに適正な抗血栓薬の選択と詳細な危険因子の評価を行い，危険因子の厳重な管理が必要である．本稿では，脳梗塞再発予防のための抗血栓療法と危険因子管理についてエビデンスをもとに解説する．

参考文献

1) Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA；Stroke Prevention by Aggressive Reduction in Cholesterol Levels（SPARCL）Investigators：High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355：549-559, 2006

2) Antithrombotic Trialists' Collaboration：Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324：71-86, 2002

3) Antithrombotic Trialists'（ATT）Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A：Aspirin in the primary and secondary prevention of vascular disease：collaborative meta-analysis in individual participant data from randomized trials. Lancet 373：1849-1860, 2009

4) Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B；PROGRESS Collaborative Group：Lower target blood pressures are safe and effective for the prevention of recurrent stroke：the PROGRESS trial. J Hypertens 24：1201-1208, 2006

5) Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ；CHARISMA Investigators：Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354：1706-1717, 2006

6) CAPRIE Steering Committee：A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events（CAPRIE). Lancet 348：1329-1339, 1996

7) Charidimou A, Kakar P, Fox Z, Werring DJ：Cerebral microbleeds and recurrent stroke risk：systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke 44：995-1001, 2013

8) Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ；MATCH investigators：Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients（MATCH）：randomised, double-blind, placebo-controlled trial. Lancet 364：331-337, 2004

9) Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S；RE-LY study group：Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke：a subgroup analysis of the RE-LY trial. Lancet Neurol 9：1157-1163, 2010

10) Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC；ARISTOTLE Committees and Investigators：Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack：a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11：503-511, 2012

11) European Atrial Fibrillation Trial（EAFT）Study Group：Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342：1255-1262, 1993

12) Fukuuchi Y, Tohgi H, Okudera T, Ikeda Y, Miyanaga Y, Uchiyama S, Hirano M, Shinohara Y, Matsumoto M, Yamaguchi T：A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis 25：40-49, 2008

13) Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y：Cilostazol stroke prevention study：a placebo-controled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9：147-157, 2000

14) Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W；ROCKET AF Steering Committee Investigators：Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack：a subgroup analysis of ROCKET AF. Lancet Neurol 11：315-322, 2012

15) Hirsh J, Bhatt DL：Comparative benefits of clopidogrel and aspirin in high-risk patient populations：lessons from the CAPRIE and CURE studies. Arch Intern Med 164：2106-2110, 2004

16) Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS：Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301：937-944, 2009

17) Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S；RE-LY Investigators：Dabigatran versus warfarin：effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44：1891-1896, 2013

18) Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A；J-RHYTHM Registry Investigators：Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation：results of the J-RHYTHM Registry. Circ J 77：2264-2270, 2013

19) 岩本俊彦：日本人脳梗塞患者に対するクロピドグレル硫酸塩の効果—脳梗塞病型別サブ解析．Geriatr Med 46：1253-1260, 2008

20) Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS：Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis：the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36：782-786, 2005

21) Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, Yu KH, Koo JS, Wong KS, Lee SH, Lee KB, Kim DE, Jeong SW, Bae HJ, Lee BC, Han MK, Rha JH, Kim HY, Mok VC, Lee YS, Kim GM, Suwanwela NC, Yun SC, Nah HW, Kim JS：Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 42：2883-2890, 2011

22) Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB：Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection：the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis（CARESS）trial. Circulation 111：2233-2240, 2005

23) Maruyama H, Fukuoka T, Deguchi I, Ohe Y, Nagoya H, Kato Y, Horiuchi Y, Hayashi T, Tanahashi N：Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke. Intern Med 52：1043-1047, 2013

24) 日本動脈硬化学会（編）：動脈硬化性疾患予防ガイドライン2012年版．東京，日本動脈硬化学会，2012

25) 日本高血圧学会高血圧治療ガイドライン作成委員会（編）：高血圧治療ガイドライン2014．東京，日本高血圧学会，2014

26) 日本糖尿病学会（編）：糖尿病治療ガイド2012-2013．東京，文光堂，2013

27) Nishiyama K, Seyama H, Okano H, Yamada S, Kurita H, Chiba A, Yamaguchi Y, Shiokawa Y：Escalation regimen of cilostazol for acute brain infarction. Intern Med 50：1559-1563, 2011

28) Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P：Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and prevention stroke or transient ischemic attack：a systemic review and meta-analysis of randomized controlled trials. Stroke 43：3298-3304, 2012

29) PROGRESS Collaborative Group：Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358：1033-1041, 2001

30) Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y：Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26：63-70, 2008

31) Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C；CSPS2 group：Cilostazol for prevention of secondary stroke（CSPS2）：an aspirin-controlled, double-blind, randomized, non-inferiority trial. Lancet Neurol 9：959-968, 2010

32) SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA：Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367：817-825, 2012

33) Stroke Prevention in Atrial Fibrillation Investigators：Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation：Stroke Prevention in Atrial Fibrillation Ⅲ randomized clinical trial. Lancet 348：633-638, 1996

34) Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ：Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev（4）：CD001246, 2009

35) Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K；JELIS Investigators, Japan：Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients：subanalysis of the JELIS trial. Stroke 39：2052-2058, 2008

36) Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K；Bleeding with Antithrombotic Therapy（BAT）Study Group：Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease：a prospective, multicenter, observational study. Stroke 39：1740-1745, 2008

37) Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU：Stroke prevention by cilostazol in patients with atherothrombosis：meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 18：482-490, 2009

38) 内山真一郎：抗血小板療法—再発予防update. Brain Nerve 65：771-782, 2013

39) Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, Okada Y, Origasa H, Ikeda Y；MAGIC Study Group：Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients：the results from the MAGIC study. J Gastroenterol 49：814-824, 2014

40) Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J；PROactive Investigators：Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke：results from PROactive（PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38：865-873, 2007

41) Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, Han Z, Tan KS, Ratanakorn D, Chollate P, Zhao Y, Koh A, Hao Q, Markus HS；CLAIR study investigators：Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis（CLAIR study）：a randomised, open-label, blinded-endpoint trial. Lancet Neurol 9：489-497, 2010

42) Yasaka M, Minematsu K, Yamaguchi T：Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40：1183-1188, 2001